The Texas Heart Institute is hosting a conference to educate the health care community about Cardiometabolic Syndrome. Photo courtesy of THI

Cardiometabolic Syndrome (CMS) is a major danger to public health around the world. No one knows this better than the Texas Heart Institute, which will host its first Cardiometabolic Syndrome Conference on Friday, August 23.

The conference’s subtitle, “A population health crisis” brings home the unpleasant reality that many recent projections anticipate drastic growth for the condition.

CMS is a combination of interrelated metabolic maladies that are risk factors not just for cardiovascular disease, but also fatty liver disease and cancer. According to THI, the underlying conditions for CMS may include hypertension, insulin resistance and type II diabetes, elevated serum lipids, and obesity, all increasingly common among the global population.

The conference will address the crisis with the help of Arianna Huffington, the founder and CEO of Thrive Global and former editor in chief of The Huffington Post Media Group. Thrive's behavior change technology may be a possible step in the right direction to prevent CMS.

“We are at a pivotal moment in the fight against cardiometabolic syndrome,” Huffington says in a press release. “This conference is not just a gathering of experts, but a catalyst for innovative thinking and actionable solutions. By integrating diverse perspectives and harnessing the collective expertise of our attendees, we can transform disease prevention strategies and improve health outcomes globally.”

THI experts will both lead the conference and participate in discussions. The co-directors are renowned cardiologists, Dr. Joseph G. Rogers, CEO and president of The Texas Heart Institute, and Dr. Stephanie Coulter, medical director for THI Center for Women’s Heart & Vascular Health. Topics will include screening and treatment guidelines, the impact of CMS on children, and integrating social determinants of health into clinical practice. Health professionals among the attendees will include cardiologists, hepatologists and endocrinologists.

“We must transcend traditional healthcare solutions to effectively tackle the rising burden of cardiometabolic syndrome,” says Rogers. “By bringing together key stakeholders and encouraging collaboration among multidisciplinary healthcare professionals, we aim to ignite groundbreaking ideas and forge novel strategies to combat this pressing health crisis."

Speaking of novel technologies, THI and BiVACOR this month reported that they successfully implanted the company's first Total Artificial Heart in a human at Baylor St. Luke’s Medical Center in the TMC.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7 Houston neighbors named to U.S. News' best places to live in 2026

Living Well

Several Houston suburbs have been crowned the best places to live in the U.S. for 2026, according to U.S. News & World Report. Sugar Land is the highest-ranked city in the Houston metro, and it ranks as the 10th best place to live in the country.

The annual list of Best Places to Live in the U.S. is designed to help readers make the most informed decisions when choosing where to settle down, using data from sources such as the U.S. Census Bureau, Department of Commerce, the Federal Reserve and the Bureau for Economic Analysis, as well as state and local sources.

For the 2026-2027 rankings, U.S. News featured 250 U.S. cities and ranked them across four livability indexes — quality of life, value, desirability, and job market — weighted by importance based on survey results of approximately 500 Americans. The rankings were also broken down state-by-state, as well as the best big, medium, and small cities overall.

Sugar Land is the No. 4 best places to live in Texas, and it soared into the No. 10 spot overall in the nation after ranking 16th last year. Sugar Land also ranks as the fourth-best mid-sized city to live in America for 2026-2027.

According to U.S. News, Sugar Land's median household income is far higher than the national average. Residents make $140,511 per year, while the average American household income is only $83,181.

Additionally, the $431,815 median home value in Sugar Land is also far greater than the $359,870 national average.

After ranking in the top 10 in the 2025 report, League City and Pearland now both rank outside the national top 10 for 2026. League City slipped from No. 6 to No. 13 this year, while Pearland dropped from No. 3 nationwide to No. 16.

These three Houston suburbs also boast highly desirable job markets for potential newcomers or current residents that want to start or change their career.

Houston proper, however, remains outside of the top 250 and is the 327th best place to live in the U.S., and it's the 60th best place to live in Texas.

Other cities in the greater Houston area that ranked among the top 100 include:

  • No. 28 – The Woodlands
  • No. 38 – Katy
  • No. 61 – Missouri City
  • No. 82 – Spring

The Lone Star State had a "strong showing" in the overall top 10 thanks to its "high affordability scores," a release said. Besides Sugar Land, three more popular Texas suburbs made the cut: Leander (No. 8) outside Austin and Dallas-Fort Worth suburbs Flower Mound (No. 3) and Frisco (No. 9).

"As prices of everyday goods continue to rise, consumers are considering affordability as a top priority when choosing a place to live," said U.S. News consumer lending analyst Erika Giovanetti. "While U.S. News’ consumer survey indicated that quality of life and affordability were close in importance, cost-of-living concerns resulted in many Americans putting what they can afford above their aspirations."

---

This article originally appeared on CultureMap.com.

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”